

Reference:	FOI.17907.25
Subject:	Treatments
Date of Request:	25 July 2025

Requested:

Hereditary Angioedema (HAE):

1. In the past 3 months [latest 3 months available] how many patients have received the following treatments [for any disease]:
 - Berinert (Human C1-esterase inhibitor)
 - Cinryze (Human C1-esterase inhibitor)
 - Orladeyo (Berotralstat)
 - Takhzyro (Lanadelumab)
 - Ruconest (Recombinant human C1-esterase inhibitor)
 - Firazyr (Icatibant injection)
 - Icatibant - any brand except Firazyr

IgA nephropathy (IG):

2. In the past 3 months how many patients have received the following treatment for any disease:
 - Octagam
 - Gamunex
 - Intratect
 - Kiovig
 - Gamten
 - Panzyga
 - Xembify
 - Cuvitru
 - Cutaquig
 - Hyqvia
3. In the past 3 months, how many patients have received any immunoglobulin treatment for the following diseases:
 - Primary immunodeficiency (PID)
 - Secondary immunodeficiency (SID)
 - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with the exact number of cases due to the low number. Where the figures in the tables have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low number of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the FoIA. This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

1. The UHB provides within the table below, the number of patients that have received the listed treatments for any disease, during the period 1 April to 30 June 2025.

Treatment	Number
Beriner (Human C1-esterase inhibitor)	*
Cinryze (Human C1-esterase inhibitor)	0
Orladeyo (Berotralstat)	0
Takhyzo (Lanadelumab)	0
Ruconest (Recombinant human C1-esterase inhibitor)	0
Firazyr (Icatibant injection)	0
Icatibant - any brand except Firazyr	0

2. The UHB provides within the table overleaf, the number of patients that have received the listed treatments for any disease, during the period 1 April to 30 June 2025.

Treatment	Number
Octagam	*
Gamunex	8
Intratec	0
Kiovig	0
Gamten	0
Panzyga	0
Xembify	0
Cuvitru	0
Cutaquig	*

3. The UHB provides within the table below, the number of patients with an immunodeficiency disease that received immunoglobulin treatment for the listed diseases, during the period 1 April to 30 June 2025.

Disease	Number
Primary immunodeficiency (PID)	*
Secondary immunodeficiency (SID)	*
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	5